Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at ...

Avalo Therapeutics, Inc.’s AVTX share price has surged by 12.29%, which has investors questioning if this is right time to ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

We came across a bullish thesis on Sana Biotechnology, Inc. (SANA) on wallstreetbets Subreddit Page by Intrepid_Web5454. In ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology ...

Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.